Notice of Proposed Sale · 144
Revolution Medicines, Inc.
RVMDNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- Revolution Medicines, Inc.
- Issuer CIK
- 0001628171
- SEC file number
- 001-39219
- Phone
- 650-481-6801
- Person for whose account securities are to be sold
- Lorence H Kim
- Relationships to issuer
- Affiliate
- Street
- 700 Saginaw Drive
- City
- Redwood City
- State / country code
- CA
- Postal code
- 94063
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 73,090 | 15,193,949.2 | 214,336,418 | 08/31/2026 | Nasdaq | J.P. Morgan Securities LLC |
Broker / market maker — proposed row 1, entry 1
- Name
- J.P. Morgan Securities LLC
- Street
- 270 Park Avenue - 10th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10017
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 07/20/2022 | Purchase | Open Market | 50,000 | N | 07/20/2022 | N/A |
| Common | 12/15/2022 | RSU Vesting | Issuer | 10,500 | N | 12/15/2022 | N/A |
| Common | 06/15/2024 | RSU Vesting | Issuer | 5,200 | N | 06/15/2024 | N/A |
| Common | 06/20/2025 | RSU Vesting | Issuer | 4,248 | N | 06/20/2025 | N/A |
| Common | 06/26/2026 | RSU Vesting | Issuer | 3,142 | N | 06/26/2026 | N/A |
Prior-sale reporting
- Nothing to report for the preceding three months
- Y
Remarks
The shares represented on this filing were received as purchase and via RSU vesting during acquired between 07/20/22 and 06/26/2026. The shares are being sold by the Kim Revocable Trust, Lorence H Kim, as Trustee.
Notice signature
- Notice date
- 08/31/2026
- Signed
- /s/ J.P. Morgan Securities LLC as agent and attorney-in-fact for Lorence H Kim
- Plan adoption dates
- 06/01/2026
Company context
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. These product candidates are investigational and have not been approved for commercial use in any indication. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit www.revmed.com and follow us on LinkedIn.